Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

which Amgen falls in, has lost 3.8%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business ...

Amgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with ...

Amgen has been a biotechnology pioneer since 1980. The global pharma company's ongoing mission is "to serve patients" and one way to complete this mission is by keeping up-to-date with the latest ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...